The focus of the industry on living beings that are human and highly controlled standards are unique to business leaders. These characteristics make the industry an ideal environment for innovation. They have resulted in major breakthroughs in biofuels, crop yields, and life-saving pharmaceuticals.
Biotech companies that are starting out have many options for revenue generation strategies, with most opting for a technology-based partnership or an out-licensing and asset creation strategy. Technology partnering can generate more revenue and reduce risk to the financials, whereas strategies for asset creation and outlicensing can yield greater returns. A increasing number of biotechs at the research stage use a hybrid strategy that combines two strategies.
People who opt for a product-centric strategy can achieve commercial success as long as they are able to bring their pipelines to the right stage and then find a major pharmaceutical partner genotec-frankfurt.de or an investor with a large sum of money. It can be a costly option. It is essential to consider the balance between opportunistic strategies in taking advantage of outside resources and the right scientific decisions regarding domestic projects.
Alternatively, the «platform» model offers an alternative method of earning revenue. It is less expensive than product-oriented research, but comes with a high risk. In this model, a biotech owns and develops its platform technology, before collaboration with big pharma firms to develop a portfolio of drug discovery projects that focus on specific disease areas (i.e. disease x within biology y). This is the strategy Advinus Therapeutics and a few others have followed.